Sugi Predict

Sugi Predict / Compounds / SCHEMBL21992735

SCHEMBL21992735

SCHEMBL21992735

C[C@H](Oc1ccc(CC(=O)c2ccc(Cl)cc2)cc1)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 2/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ NPC1 O15118 2/20 0.57
▸ RAB9A P51151 2/20 0.57
▸ MAPT P10636 1/20 0.56
▸ PPARG P37231 8/20 0.51
▸ PPARA Q07869 7/20 0.51
▸ TBXAS1 P24557 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48
▸ KMT2A Q03164 1/20 0.47
▸ MAP4K4 O95819 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21991795 1.00 EPHX2 (0.60) EPHX2L3MBTL1NPC1RAB9AMAPT
SCHEMBL21991367 1.00 EPHX2 (0.60) EPHX2L3MBTL1NPC1RAB9AMAPT
SCHEMBL21991466 0.86 L3MBTL1 (0.55) EPHX2L3MBTL1NPC1RAB9AMAPT
SCHEMBL21992612 0.86 L3MBTL1 (0.55) EPHX2L3MBTL1NPC1RAB9AMAPT
SCHEMBL21991473 0.85 EPHX2 (0.63) EPHX2L3MBTL1NPC1RAB9AMAPT
SCHEMBL21992473 0.85 NPC1 (0.54) EPHX2L3MBTL1NPC1RAB9AMAPT
SCHEMBL10967275 0.84 EPHX2 (0.64) EPHX2PPARGPPARATBXAS1CYP1A2
SCHEMBL21991313 0.84 L3MBTL1 (0.55) EPHX2L3MBTL1NPC1RAB9AMAPT
SCHEMBL2399722 0.83 CYP1A2 (0.65) EPHX2PPARGPPARACYP1A2GAA
SCHEMBL607372 0.83 CYP1A2 (0.65) EPHX2PPARGPPARACYP1A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 — — US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 — — US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 — — US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 — — US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 — — US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 EPHX2 1344/4885L3MBTL1 1170/4885NPC1 233/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 EPHX2 1344/4885L3MBTL1 1170/4885NPC1 233/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 EPHX2 1344/4885L3MBTL1 1170/4885NPC1 233/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 EPHX2 1344/4885L3MBTL1 1170/4885NPC1 233/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 EPHX2 1344/4885L3MBTL1 1170/4885NPC1 233/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 EPHX2 1344/4885L3MBTL1 1170/4885NPC1 233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.